Retinitis Pigmentosa News and Research RSS Feed - Retinitis Pigmentosa News and Research

Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
New gene therapy restores some sight in people born with inherited form of blindness

New gene therapy restores some sight in people born with inherited form of blindness

A new gene therapy has restored some sight in people born with an inherited, progressive form of blindness. The technique replaces a defective gene in the eye with a normal working copy of the gene using a single injection. [More]
Optogenetics offers a promising therapy for retinal degeneration

Optogenetics offers a promising therapy for retinal degeneration

For a few years now optogenetics has been seen as a very promising therapy for progressive blindness, for example when it is a result of retinal degeneration. [More]
Study: New device helps people who lost vision due to blinding genetic disease

Study: New device helps people who lost vision due to blinding genetic disease

Research presented today at the 117th Annual Meeting of the American Academy of Ophthalmology shows promising data about a device that helps people who have lost their vision due to a blinding genetic disease to recognize common objects. [More]
Key marker in blood and urine identifies genetic mutations in gene responsible for RP

Key marker in blood and urine identifies genetic mutations in gene responsible for RP

Research led by physician-scientists at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has produced a breakthrough discovery in diagnosing retinitis pigmentosa, a blinding disease that affects about 1 in 4,000 people in the United States. [More]
Barcelona to host European Drosophila Research Conference

Barcelona to host European Drosophila Research Conference

From 16 to 19 October, more than 700 international scientists will attend the European Drosophila Research Conference, the most important European conference focused on basic and biomedical research that uses the fly fruit, Drosophila melanogaster, as a model system. [More]
Researchers make breakthrough discovery in diagnosing retinitis pigmentosa

Researchers make breakthrough discovery in diagnosing retinitis pigmentosa

Research led by physician-scientists at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has produced a breakthrough discovery in diagnosing retinitis pigmentosa, a blinding disease that affects about 1 in 4,000 people in the U.S. [More]
Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research. [More]
Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

... [More]
Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

... [More]
Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. [More]
Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers. [More]
Research holds promise for developing treatments for retinitis pigmentos

Research holds promise for developing treatments for retinitis pigmentos

One of the leading causes of inherited blindness in humans, retinitis pigmentosa, is analogous to retinal dystrophies that lead to blindness in dogs. Because of their similarities, identifying gene mutations underlying several types of canine retinal dystrophies has suggested courses for research on RP in humans. These advances are significant for both humans and dogs. [More]
Researchers identify mutation in CNGB1 gene causing PRA in Phalene and Papillon

Researchers identify mutation in CNGB1 gene causing PRA in Phalene and Papillon

Professor Hannes Lohi's research group at the University of Helsinki and Folkh-lsan Research Center, Finland, has identified a mutation in CNGB1 gene, causing progressive retinal atrophy (PRA) in the Phalene and Papillon dog breeds. [More]
Research findings offer clues to the origin of retinal disorders later in life

Research findings offer clues to the origin of retinal disorders later in life

Scientists are developing a clearer picture of how visual systems develop in mammals. The findings offer important clues to the origin of retinal disorders later in life. [More]

Vanderbilt offers first FDA-approved bionic eye for treatment of retinitis pigmentosa

Vanderbilt University Medical Center has been chosen as one of 12 sites in the United States to offer the first FDA-approved bionic eye for the treatment of retinitis pigmentosa (RP). [More]

University of Florida receives RPB Sanders Construction grant

Research to Prevent Blindness has awarded a prestigious, one-time laboratory grant of $600,000 to the Department of Ophthalmology at the University of Florida, College of Medicine. The newly created laboratory will be permanently named the RPB Mildred Krahmer Sanders and William Clifford Sanders Laboratory for Vision Research. [More]
UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

University Hospitals Eye Institute will be one of the first medical centers in the United States to offer the Argus II Retinal Prosthesis System. [More]
Effective method to restore sight to patients with blinding diseases

Effective method to restore sight to patients with blinding diseases

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration [More]

EMA grants Sucampo orphan drug designation for unoprostone isopropyl to treat retinitis pigmentosa

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today. [More]
Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. [More]